THRO>IBOSIS Printed
RESEARCH in the
LETTER
THE
States
TO
FIBRINOGENOLYTIC
THE
COLLEN,
N.
Laboratory
of
University
In it
has
logi
a
letter
been
co I
over”
and
for
this
pathway This
20
similar (3)
%
of those
; b) the 25
rivatives the
high
In
fibrinogen
which
may
lonamino
fied
et
caproic
Blomback material
and
is
balance
Murano
al acid
was
(EACA)
reduced
25
185,
under
1973) physio-
pathway” %
suggests
of
no
of
the less
not
the while
ethanol
turna
of in
such
role
to
and
may
not
when the
yield that
in
of of 491
intact
for
made
: a)
dethat
digestion b)
operates
that at
the
coa-
similar
valid.
glycine
degraded
occur
fibrinogen
and
rabbits
be
fibrinogen
to
proteolytic
precipitation
humans
fibrinogen
seems
were
partial
Ao(chains,
solubility
solubility
assumptions
ethanol
in
low
human
posesses
degraded
rabbits
high
: a)
precipitation,
digestion
due
that,
observations
containing
two
in
found
Blomback,
that
for
(2),
of
assumptions
(5)
2,
catabolic
following
fibrinogen
during
these
maior
humans
by
plasmic
reasoning,
occurred
However,
the
plasma
formation
heterogeneity have
Research
accounts for
23.1.1974.
evidence
a
rabbits
on
labeled
the
this
is
material by
of
gulation-fibrinolysis rates.
fresh
solubility
through
(4).
based
from
turnover %
(Thromb.
“conclusive
in
form Copley)
(1).
was
obtained
VERSTRAETE
Coagulation,
in revised Editor A.L.
information
man”
p re p ared
to
about
in
conclusion
fibrinogen, over
“available
M.
Belgium.
is
pathway
:
Leuven,
fibrinogenolysis
“this
that
there
CATABOLlsM
Department,
editors-in-chief
that
circumstances, that
of
L.euven,
the
claimed
fibrinogen,
Blood
10.12.1973; Accepted by
to
FIBRINOGEN
and
Research
3000
(Received
OF
REPLY.
SEMERARO
Medical
1974 Inc.
EDITORS-IN-CHIEF
PATHWAY A
D.
4, pp. 491-496, Pergamon Press,
vol. Vnir;ed
was
replaced
purification Aa(chains A
by method
in was
the
epsiof puri-
increased.
492
ON THE FIBRINOGENOLYTIC
Since
the
degradation
assumed trace
that
fibrinogen
quantities
completely
of
90,000
during
capable
to
convert
lysine of
is
low
much
p lasminogen particularly ring
more
susceptible
(10).
It
The of
data
But
derivatives. nificant The
finding
(11)
or
slower
gulation
as
a
studies
fibrinopeptide
A
the
fibrinogen
lease. than olysis
If in
cal nogen
pathway during
indicate
et that
in
could
also
be
before of the
is
possible much
purification
plasmino-
are
does
occur
du-
with
possibility
normal
of in
of
ar-
in
man
likely
higher
this
factor to
on
at that
a-
solubility
species
a
infusion
in
man
deficiencies
exclude in
in
(12)
vivo
man.
coa-
Further-
radioimmunoassays only
2-3
of
percent
fibrinopeptide a
much in
sig-
coagulation.
heparin
through
operates
significant
intravascular
conditions
mediated
a
fibrinogen
based
even
the
A
slower
vivo
of re-
rate
fibrinogen-
slower.
accepting
fibrinogen
of
be
and
in
coprecipitates
that
tends
(13)
are
plasminogen
rabbits
coagulation
al
been
native
the
during
pathway
coagulation it
by
conditions,
Nossel
of
the
which
in
revealed
turnover
metabolic of
vivo
rabbits
Thus,
normal
in
III
NH2-termi-
than
formation
consumed
congenital
turnover
in
may
in
maior
the
more,
with
than
is
fibrinogen
patients
that
through also
to
of
obvious.
indicate
study
approxi-
enhanced
plasmin
procedure,
catabolized
of
plasmin
lysine
plasminogen
becomes
case
have
of
acid
degradation, some
(4)
amounts
bonds
the
weight
must
markedly
to
not
fraction
molecular
NH2-terminal
some
fractionation
fibrinogen
the
is
in
Cohn
which
Trace
activation that
7).
a
to
may
weight
glutamic
and
proteolytic
same
of
that
in
conversion
EACA,
Sherman
the
amount
this
alone
occur
(6,
with
exposed
fibrinogen.
molecular acid
8).
-terminal
to
to
is
a
to
lysine,
NH2
degradation
fibrinogen
has
(6,
appears
the
of
seems
authors
be
of
plasminogen
Because
fibrinogen
not
thus
throughout
tefactual
mount
of
fractionation.
fibrinogen
is
amounts
constantly
degradation
NH2-terminal
(9),
abolished,the
EACA
glutamic
of
purified
susceptible
Cohn
-terminal
Vo1.4,No.3
However,
protection
fractionation
plasminogen
presence
fibrinolytic
and
the
may
enzymes.
amounts
82,000
generated
completely
plasminogen
NH2
significant
not
circulation
incomplete
and
approximately
the
vitro
Circulating
contains
gen
in
such
plasminogen.
nal
in
was
proteolytic
prevent
Actually
mately
process
PATHWAY
that
fibrinogenolysis
catabolism procedure
in
man,
is
a
proteolysis
employed
by
maior of Mosesson
physiologihuman et
fibrial.
03 THE FIBRISOGEXOLYTIC
vo1.4,?io.3
should and
be low
excluded
and/or
molecular
the
precursor-product
weight
fibrinogen
we
some
433
PATHWAY
relationship
should
also
be
between
demonstrated
in
high vivo
in
of
hu-
man. TO
this
man
fibrinogen
(14).
Human
end
isolated plasma
brinogen-substituted degradation X,
Y
fered
fibrinogen lulose
eluted was
protein
derivatives ded
Ati
the
second
is
(16)
of chains (BB
the
urea-O.025
alkylated (fig
&
in BB
chain)
and
Ao( third
and
thrombin-modified
a
MW
were the
M
acetate
its
chains
and
of
fiplasmic
100,000
washed
fibrinogen buffer
out
with
was
virtually
pH
separated
(fragments
5.0. by
buf-
The
CM-cel-
I).
three peaks, en A-LK chains
(designated
with
and
chromatography
fibrinogen
proteins EACA
composition
affinity
of
retain D
chain
by
column
columns
chromatography
eluted
a
fragment
8 M
and
chromatography
through
and
the
plasma
Not-adsorbed
with
reduced
on
frozen
Such
Trasylol
: CM-cellulose
Figure The
(15).
containing
quantitatively
passed
containing
D”)
experiments
fresh
agarose.
“big
saline
from was
products
and
did
+ (16)
of reduced corresponding of )
(Aachain)
are
and alkylated fibrinogen. to the carboxymethylated
fibrinogen, eluted peaks.
as in
the
indicated. valley
Degrabetween
ON THE FIBRINOGENOLlTIC
The 6
chromatography cm
column
0.025 tic
M
of
The
linear
gradient
buffer
and
The
M
75
%#
8
the
%
gradient
changed
at
changed
at
M
rate
of
as
the
ml
pH
20
the
%
per
24
8
M
hr as
hr
of
due
ace-
with
a
The
gra-
analysis
time. of
the
eluate
principle,
to
urea-
starting
the
(in
x
with
transmission
constant
of
cm2
4.3
4.3
transmission
kept
1
buffer.
using
when
rate
8
a
to
limiting
device,
was
reduced
lowered
5.2
When
to with
was
acetate
linearly
nm.
a
flow
pH
composition
linearly
a
app lied
equilibrated
pH
ultrograd
280
samples
urea-O.025
LKB
at
the
acetate
was
75
mg
CM-52)
which
M
M
with
the
of
of
urea-O.025
above
50
developed
composition
was
actually
was
obtained
on
(Whatman
buffer
composed
gradient
below
CM-cellulose
column
8
was
eluate
performed
sodiumacetate
acid.
dient
was
PATH-b-_&y
was but
the
electric
BB
and
circuiting). This chains, re
procedure
and
in
degraded
than
90
and
Ao(
between
a
very
minor
fraction
Thus
our
significant
should
without
(less
of
from
fresh
processed
gen
degradation
at
Further
as
a
major
experiments
brinogen, as
summary
well
as
of
sustain
(17)
third
the
half
a
that
the
fibrinogen
corresponded
in
has dozen
for
conditions A<
samples
was
by
We
presently
investigating
reproduaffinity
healthy
conditions
chains.
are
prepared from
protective
the
found
only
degraded
obtained
more
to
were
normal
plasma, are
better
different
accounted
that
fibrinogen on
whe-
peak.
view
far
the
Ao(
region
was
Ao(chains
they
Ao(
the
of
peaks
but
the
in
recovery
degraded
thus
frozen
material
protein
chains
the
blood
do-
whether
shows
any
fibrino-
all. our
contention
catabolic
along
metabolic
and
circulating
under
on
possibly
%)
precautions.
plasma,
genolysis
the
stressed
fresh
In
not
of
electrophoresis
Ao(
5
of
The
Some
and
than
do
be
special
amount
second
Bt3
separation
(16).
first,
obtained
chromatography nors
small
respectively.
results
chromatograms
clear
gel
the
amount
It
a
a
present
the
chains
region
cible.
only
are
that
the
The
in
SDS-polyacrylamide
in
a
of
chains
revealed Bi3
)51
elution
Ao(
%.
fractions
resulted
the
is
that
the
pathway
in
man
molecular
the
studies
lines
hypothesis still
composition described
similar
to
in
those
of
remains
in to
of ------_-circulating present
letter
performed
by
vivo be
fibrinoproven.
_ human are
Sherman
fi-
required in
rab-
bits. It degradation
was
proposed
products
of
to the
the
Subcommittee
International
on
Committee
fibrinogen of
and
Thrombosis
fibrir+gen) and
Hae-
ON THE
Vo1.4,No.3
mostasis forms
with
represent
degraded
(low
to
Ad
circulating
solubility such
1973)
(Vienna,
include
chains,
would
PATHWAY
the
definition
the
assumption
protein.
weight) be
in
under
coagulable
molecular
a decision
FIBRINOGENOLYTIC
Since
fibrinogens
it
may
495
of
fibrinogen
that
these
is possible be
also
the
would
that
preparation
also
these
high
artefacts
premature.
ACKNOWLEDGEMENTS _-~--That by
a better
CM-cellulose
could The been
of
of
chromatography
be obtained details
separation
the
was
with
mentioned
procedure,
S-Carboxymethylated the
to one
as worked
use of of out
the
us (D.C by
fibrinogen
Dr.
LKB .)
chains
ultrograd
by
Dr.
Murano
device
G. have
Murano. not
yet
published.
REFERENCES
1.
MOSESSON, M.W. The fibrinogenolytic holism. Thromb. Res., 2, 185, 1973.
2.
MOSESSON, M.W. of human fibrinogen T966.
3.
MOSESSO N, M.W., FINLAYSO N, J.S., UMFLEET, R.A. and GALANAKIS, D. Human fibrinogen heterogeneities. I. Structural and related studies of plasma fibrinogens which are high solubility catabolic intermediates. J. Biol. Chem. 247, 5210, 1972.
4.
SHERMAN, L.A. ways of catabolism.
5.
and SHERRY, of relatively
Fibrinogen J. Lab.
MURANO, G., WIMAN, : some characteristics Thromb. Res. 1, 161,1972.
9en
S. high
pathway
of
fibrinogen
The preparation and solubility. Biochem.
turnover : demonstration Clin. Med. 79, 710,
B. and BLOMBACK, of its S-carboxymethyl
cata-
properties 5, 2829,
of multiple 1972.
B. Human derivative
path
fibrinochains.
6.
WALLEN, P. and WIMAN, 8. Characterization of human plasminoI. On the relationship between different molecular forms of gen. plasminogen demonstrated in plasma and found in purified preparations. Biochim. Biophys. Acta 221, 20, 1970.
7.
COLLEN, D., ONG, E.B. and JOHNSON, plasminogen. Fed. Proc. 31, 229, 1972.
8.
WALLEN, P. and WIMAN, B. gen. II. Separation and partial lar forms of human plasminbgen. 1972.
A. J.
Native
Characterization of human characterization of different Biochim. Biophys. Acta,
human
plasminomolecu257, 122,
496
ON THE FIBRINOGENOLYTIC
H., MOLLA, glutamic acid Thromb. Res.
Vo1.4,No.3
PATHWAY
9.
CLAEYS, terminal plasmin.
A. and VERSTRAETE, to NH2 -terminal iysine (in press).
TO.
CLAEYS, properties Submitted
IT.
COLLEN, tabolism siological
12.
TYTGAT, G., COLLEN, D. and VERMYLEN, J. Metabolism and distribution of fibrinogen. II. Fibrinogen turnover studies in polycythae mia, congenital afibrinogenaemia and thrombocytosis, haemophi lia A, during streptokinase therapy. Brit. J. Haemat. 22, 701, 1972.
13.
NOSSEL, H.C., CANFIELD, R.E. and BUTLER, Jr., V.P. fibrinopeptide A concentration as on index of intravascular tion. IV Cong. Int. Sot. Thrombosis Haemostasis, Vienna, stract volume, p .237.
T4.
HEENE, tives on 2, 137,
15.
REUTERBY, J. and BLOMBACK, B. Adsorption of KYDRYK, D., plasmic fragment D to thrombin-modified fibrinogen-Sepharose. Thromb. Res. 2, 297, 1973.
16.
MURANO, G., WIMAN, B., BLOMBACK, M. B. Preparation and isolation of the S-carboxymethyl of human fibrinogen. FEBS Letters 14, 37, 1971.
17.
McDONAGH, J., MESSEL, and BLOMBACK, NO, G. gen and fibrin chains by an trophoresis method. Biochim.
H. and VERMYLEN, of human plasminogen. for publication. D., TMGAT, and distribution conditions in
and D.L. insulubilized 1973.
J.
Physicochemical and Effect of epsilonamino
G., CLAEYS, of fibrinogen. humans. Brit.
MATTHIAS, fibrinogen
M. Conversion of NH2human plasminogen by
F.R. and
proenzyme caproic acid.
H. and PIESSENS, R. MeI. Fibrinogen turnover in phyJ. Haemat. 22, 681, 1972.
Adsorption of fibrinogen fibrin monomer. Thromb.
and
Plasma coagula1973, Ab-
derivaRes.
BLOMBACK, derivative chains
H., McDONAGH, R.P., Jr., MURAB. Molecular weight analysis of fibrinoimproved sodium dodecyl sulfate gel elecBiophys. Acta, 257, 135, 1972.